Abstracts tagged "IL-6"

Abstract Number: 1625 • 2016 ACR/ARHP Annual Meeting
Analysis of a Phase 3 Study Evaluating the Efficacy of Sirukumab, an Anti-IL-6 Cytokine Monoclonal Antibody, Across Subgroups in Patients with Active Rheumatoid Arthritis Despite Treatment with Disease-Modifying Anti-Rheumatic Drugs
Carter Thorne¹, George Karpouzas², Tsutomu Takeuchi³, Shihong Sheng⁴, Weichun Xu⁴, Ravi Rao⁵, Kaiyin Fei⁴ and Benjamin Hsu⁴, ¹University of Toronto and Southlake Regional Health Centre, Newmarket, ON, Canada, ²Division of Rheumatology, Harbor-UCLA Medical Center, Torrance, CA, ³Division of Rheumatology, Keio University School of Medicine, Tokyo, Japan, ⁴Janssen Research & Development, LLC, Spring House, PA, ⁵GSK Medicines Research Centre, Stevenage, Hertfordshire, United Kingdom
Background/Purpose: Sirukumab is a human monoclonal antibody that selectively binds to the IL-6 cytokine with high affinity, and is under development for rheumatoid arthritis (RA)…
Abstract Number: 2104 • 2016 ACR/ARHP Annual Meeting
Treatment with Tocilizumab Decreases CXCL13 Expression in Cultured Temporal Arteries from Patients with Giant Cell Arteritis
Nekane Terrades-Garcia¹, Joana Daradoumis², Ester Planas-Rigol², Marc Corbera-Bellalta¹, Sergio Prieto-González², Georgina Espígol-Frigolé² and Maria C. Cid³, ¹Vasculitis Research Unit. Department of Autoimmune Diseases, Hospital Clínic. University of Barcelona. IDIBAPS, Barcelona, Spain, ²Department of Autoimmune and Systemic Diseases, Hospital Clínic. University of Barcelona. IDIBAPS, Barcelona, Spain, ³Autoimmune and Systemic Diseases, Hospital Clínic. University of Barcelona. IDIBAPS, Barcelona, Spain
Background/Purpose: IL-6 has been considered a biomarker of disease activity in GCA and a potential therapeutic target. However, the functional role of IL-6 in GCA…
Abstract Number: 2142 • 2016 ACR/ARHP Annual Meeting
Identification of Novel Molecules Targeting Cartilage Aging As Osteoarthritis Therapeutics
Beatriz Carames¹, Uxia Nogueira-Recalde¹, Eduardo Dominguez², Maria I. Loza³ and Francisco J. Blanco^1,4, ¹Cartilage Biology Group. Rheumatology Division, INIBIC-Hospital Universitario A Coruña, A Coruña, Spain, ²BioFarma Research Group. University of Santiago de Compostela, Santiago de Compostela, Spain, ³BioFarma Research Group. University of Santiago de Compostela, santiago de Compostela, Spain, ⁴Rheumatology Division, INIBIC-Complejo Hospitalario Universitario A Coruña (CHUAC), La Coruña, Spain
Background/Purpose: Effective treatments for Osteoarthritis (OA) are not available. In aging-related diseases, including OA, failure of cellular homeostasis mechanisms, such as autophagy can cause extracellular…
Abstract Number: 2604 • 2016 ACR/ARHP Annual Meeting
Ultrasound and Immunological Changes and Associations after One Year of IL-6/IL- 6R Blockade with Tocilizumab in Rheumatoid Arthritis Patients
Cesar Diaz-Torne¹, Juan Jose De Agustin², Patricia Moya¹, Maria A. Ortiz³, Delia Reina⁴, Carme Moragues⁵, Sergi Ros⁶, Emili Gomez⁷, Enrique Casado Burgos⁸, Eli Garcia⁹, Manel Pujol¹⁰, Maria Pilar Lisbona Perez¹¹, Andrés Ponce¹², V Torrente¹³, P. Estrada¹⁴, Silvia Vidal³ and ECOCAT group, ¹Rheumatology, Hospital Universitari de la Santa Creu i Sant Pau, Barcelona, Spain, ²Rheumatology, Hospital Baix de Llobregat, Barcelona, Spain, ³Institut de Recerca Sant Pau, Barcelona, Spain, ⁴Rheumatology, Hospital de Sant Joan Despí Moisès Broggi, Barcelona, Spain, ⁵Rheumatology, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain, ⁶Rheumatology, Hospital de Viladecans, Viladecans, Spain, ⁷Rheumatology, Hospital Clínic, Barcelona, Spain, ⁸Hospital Universitari Parc Taulí, Sabadell, Spain, ⁹Rheumatology, Hospital de Mollet, Mollet, Spain, ¹⁰Hospital Mútua de Terrassa, Terrassa, Spain, ¹¹Rheumatology, Hospital de Sabadell, Sabadell, Spain, ¹²Rheumatology. Internal Medicine, Hospital General de Granollers, Granollers, Spain, ¹³Hospital de L'Hospitalet, L'Hospitalet de Llobregat, Spain, ¹⁴Rheumatology, Hospital Moises Broggi, Barcelona, Spain
Background/Purpose: Management of RA patients has improved in the last two decades in part with the use of ultrasound (US) in daily clinical practice. The…
Abstract Number: 2620 • 2016 ACR/ARHP Annual Meeting
Retrospective Analysis for Determining the Signs and Symptoms of Infections before They Become Serious in Tocilizumab-Treated RA Patients Using a Postmarketing Adverse Events Reporting Database
Tatsuya Atsumi¹, Yoshiaki Ando², Yukiko Hayashi², Shinichi Matsuda², Riwa Tanaka², Nobuhiro Takagi² and Ayako Nakasone², ¹Division of Rheumatology, Endocrinology and Nephrology, Hokkaido University Graduate School of Medicine, Sapporo, Japan, ²Chugai Pharmaceutical Co. Ltd., Tokyo, Japan
Background/Purpose: Given that tocilizumab (TCZ) directly inhibits IL-6 signaling and strongly suppresses the inflammatory reaction, there is concern that the signs and symptoms associated with…
Abstract Number: 3145 • 2015 ACR/ARHP Annual Meeting
Efficacy and Safety of Modified-Release Prednisone in Patients with Polymyalgia Rheumatica: Results of a Multicenter, Randomized, Active-Controlled Phase 3 Study
Maurizio Cutolo¹, Michael Hopp², Stefan Liebscher², Bhaskar Dasgupta³ and Frank Buttgereit⁴, ¹Research Laboratory and Academic Division of Clinical Rheumatology, Department of Internal Medicine, University of Genova, Genova, Italy, ²Medical Science, Mundipharma Research GmbH & Co. KG, Limburg, Germany, ³Rheumatology, Southend University Hospital, Essex, United Kingdom, ⁴Department of Rheumatology and Clinical Immunology, Charité – Universitätsmedizin Berlin, Berlin, Germany
Background/Purpose: Polymyalgia rheumatica (PMR) is characterized by persisting proximal pain and morning stiffness of the neck, shoulder and hip girdles of 2 weeks' duration, an…
Abstract Number: 200 • 2015 ACR/ARHP Annual Meeting
Mast Cell Regulation of Aortic IL-6 Expression Involves Histamine-1 Receptor, Suppressor of Cyotkine Signaling-1 and IL-10
Vineesh Raveendran¹, Jason Springer², Donald Smith³, Mehrdad Maz⁴ and Kottarappat Dileepan¹, ¹Department of Medicine, University of Kansas Medical Center, Kansas City, KS, ²Division of Allergy, Clinical Immunology and Rheumatology, University of Kansas Medical Center, Kansas City, KS, ³University of Kansas Medical Center, Kansas City, KS, ⁴Division of Rheumatology, University of Kansas Medical Center, Kansas City, KS
Background/Purpose: IL-6 plays an important role in the pathogenesis of large vessel vasculitis. Lipopolysaccharide (LPS), acting through toll-like receptor 4, enhances both the aortic expression…
Abstract Number: 253 • 2015 ACR/ARHP Annual Meeting
Multiple Serum Cytokine Profiling to Identify Specific Molecular Networks in Attacks of Familial Mediterranean Fever
Tomohiro Koga¹, Kiyoshi Migita², Shuntaro Sato³, Masataka Umeda⁴, Shoichi Fukui⁵, Ayako Nishino⁴, Shinya Kawashiri⁶, Naoki Iwamoto⁵, Kunihiro Ichinose⁵, Mami Tamai⁵, Hideki Nakamura⁵, Tomoki Origuchi⁷, Yukitaka Ueki⁸, Kazunaga Agematsu⁹, Katsumi Eguchi¹⁰ and Atsushi Kawakami⁴, ¹Departments of Immunology and Rheumatology, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan, ²Department of Rheumatology and Clinical Research Center, Nagasaki Medical Center, Omura, Japan, ³Clinical Research Center, Nagasaki University Hospital, Nagasaki, Japan, ⁴Department of Immunology and Rheumatology, Nagasaki University, Nagasaki, Japan, ⁵Department of Immunology and Rheumatology, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan, ⁶Department of Public Health, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan, ⁷Department of Rehabilitation Sciences, Nagasaki University, Nagasaki, Japan, ⁸Rheumatic and Collagen Disease Center, Sasebo Chuo Hospital, Sasebo, Japan, ⁹Department of Infectious Immunology, Shinshu University, Graduate School of Medicine, Shinshu, Japan, ¹⁰Department of Rheumatology, Sasebo Chuo Hospital, Sasebo, Japan
Background/Purpose: Familial mediterranean fever (FMF) is caused by a number of mutations of the MEFV gene, coding for a protein named pyrin that acts as…
Abstract Number: 798 • 2015 ACR/ARHP Annual Meeting
Keratinocyte-Associated IL-6 Is Elevated in Cutaneous Lupus Rashes and Production of IL-6 By Keratinocytes Is Enhanced in Non-Involved Lupus Skin
Jasmine Stannard¹, Emily Myers², Tamra J. Reed³, Lori Lowe⁴ and J. Michelle Kahlenberg⁵, ¹Int. Medicine/Rheumatology, University of Michigan, Ann Arbor, MI, ²Georgetown University, Washington, DC, ³Internal Medicine, Rheumatology, University of Michigan, Ann Arbor, MI, ⁴Dermatology, University of Michigan, Ann Arbor, MI, ⁵Internal Medicine, Division of Rheumatology, Division of Rheumatology, University of Michigan Medical Center, Ann Arbor, MI
Background/Purpose: Systemic lupus erythematosus (SLE) is a devastating autoimmune disease with severe complications such as immune-complex mediated nephritis and scarring skin lesions. Treatment modalities for…
Abstract Number: 1153 • 2015 ACR/ARHP Annual Meeting
Colonic Intraepithelial Lymphocytes Produce IL-6 in Response to Resident Bacteria to Modulate Epithelial Barrier Function
Gaurav Mehta¹, Emilie H. Regner², Neha Ohri², Sean P. Colgan² and Kristine A. Kuhn², ¹Division of Rheumatology, University of Colorado School of Medicine, Aurora, CO, ²University of Colorado School of Medicine, Aurora, CO
Background/Purpose: Dysbiosis of colon bacteria has emerged as a likely contributor to diseases such as rheumatoid arthritis and spondyloarthropathies. Interactions between the microbiota and distal…
Abstract Number: 1405 • 2015 ACR/ARHP Annual Meeting
Tocilizumab Serum Levels and Antidrug Antibodies and Its Relationship with Disease Activity in Rheumatic Diseases
Samantha Rodriguez-Muguruza¹, Melania Martínez-Morillo¹, Juana Sanint², Bibiana Quirant Sr.³, Aina Teniente Sr.⁴, Agueda Prior⁵, Anne Riveros-Frutos⁶, Susana Holgado⁷, Maria Lourdes Mateo⁷, Alejandro Olivé⁸, Jeronima Cañellas⁵ and Xavier Tena⁷, ¹Rheumatology, Hospital Universitario Germans Trias i Pujol, Barcelona, Spain, ²Rheumatology, Hospital Universitario Germans Trias i Pujol, Badalona, Spain, ³Immunology, Hospital Universitari Germans Trias i Pujol, Barcelona, Spain, ⁴immunology, Hospital Universitari Germans Trias i Pujol, barcelona, Spain, ⁵Rheumatology, Hospital Universitari Germans Trias i Pujol, Barcelona, Spain, ⁶Microbiology, Hospital Universitario Germans Trias i Pujol, Badalona, Spain, ⁷Rheumatology, Hospital Germans Trias i Pujol, Badalona, Spain, ⁸Hospital Germans Trias i Pujol, Badalona, Spain
Background/Purpose: Tocilizumab (TCZ) is a humanized anti-IL-6 receptor-blocking monoclonal antibody used for the treatment of rheumatoid arthritis (RA), idiopathic juvenile arthritis (IJA) and off-label in…
Abstract Number: 1426 • 2015 ACR/ARHP Annual Meeting
The Effect of Anti-Interleukin-6 Receptor Antibody in Ovariectomized Mice
Sho Kato¹, Hiroki Wakabayashi², Taro Nakagawa³, Yohei Naito³, Takahiro Iino⁴ and Akihiro Sudo⁵, ¹Department of Orthopaedic Surgery, Mie University Graduate School of Medicine, Tsu City, Japan, ²Orthopaedic Surgery, Mie University Graduate School of Medicine, Tsu City, Japan, ³Department of Orthopaedic Surgery, Mie University Graduate School of Medicine, Tsu City, Mie, Japan, ⁴Mie University Graduate School of Medicine, Mie University Graduate School of Medicine, Tsu City, Mie, Japan, ⁵Orthopaedic surgery, Mie University Postgraduate School of Medicine, Tsu-city, Japan
Background/Purpose: Osteoporotic patients with no evidence of fractures sometimes experience vague low back pain. Bone pain associated with bone metastasis may also be related to…
Abstract Number: 1530 • 2015 ACR/ARHP Annual Meeting
Neutrophil Function and Survival Unaffected in Healthy Subjects Following Single Administration of Tocilizumab
Laurence Lok¹, Jatinder Juss¹, Neda Farahi¹, Chrystalla Loutsios¹, Chandra Solanki², Adrien Michael Peters³, Sophie Dimonaco⁴, Francis Donaldson⁴, Benjamin Porter-Brown⁴ and Edwin Chilvers¹, ¹Department of Medicine, University of Cambridge School of Clinical Medicine, Cambridge, United Kingdom, ²Department of Nuclear Medicine, Cambridge University Hospitals, Cambridge, United Kingdom, ³Division of Clinical and Laboratory Investigation, Brighton and Sussex Medical School, Brighton, United Kingdom, ⁴Roche Products Ltd., Welwyn Garden City, United Kingdom
Background/Purpose: Decreases in circulating neutrophil counts have been observed in adults with rheumatoid arthritis (RA) and children with systemic or polyarticular juvenile idiopathic arthritis treated…
Abstract Number: 1635 • 2015 ACR/ARHP Annual Meeting
Development of New Bioassay System Measuring Inhibitory Strength of IL-6/STAT3 Signal Under Tocilizumab Treatment in Rheumatoid Arthritis Patients
Shuntaro Saito¹, Katsuya Suzuki¹, Kunihiro Yamaoka¹ and Tsutomu Takeuchi², ¹Division of Rheumatology, Department of Internal Medicine, Keio University School of Medicine, Tokyo, Japan, ²Keio University School of Medicine, Tokyo, Japan
Background/Purpose: Tocilizumab (TCZ) is a IL-6 receptor blockade, administered intravenously every 4 weeks and efficiently inhibits IL-6/STAT3 signaling pathway. We have previously reported the usefulness…
Abstract Number: 1682 • 2015 ACR/ARHP Annual Meeting
Suppression of Chronic Arthritis By a Novel Nuclear Factor of Activated T-Cell 5 (NFAT5) Inhibitor
Wan-Uk Kim¹, Eun-Jin Han², Chong-Hyeon Yoon³, Ki-Jo Kim⁴, Seung-Ah Yoo⁵, Bong Ki Hong⁵ and Saseong Lee⁵, ¹Internal Medicine, Seoul St. Mary’s Hospital, The Catholic University of Korea, Seoul, South Korea, ²Institute of Bone & Joint Disease, The Catholic University of Korea, Seoul, South Korea, ³Division of Rheumatology, Department of Internal Medicine, College of Medicine, The Catholic University of Korea, Seoul, South Korea, ⁴St. Mary's Hospital, Seoul, South Korea, ⁵Institute of Bone and Joint Diseases, The Catholic University of Korea, Seoul, South Korea
Background/Purpose: We reported that nuclear factor of activated T-cells 5 (NFAT5), originally identified as an osmo-protective transcription factor, has a critical role in the pathogenesis…

« Previous Page
1
…
3
4
5
6
7
…
9
Next Page »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].